Stem Cell Therapy for Liver Disease
Support liver regeneration and reduce fibrosis with MSC regenerative therapy.
Understanding Liver Disease
Liver disease encompasses a range of conditions that impair liver function, including non-alcoholic fatty liver disease (NAFLD), hepatitis, cirrhosis, and autoimmune liver disorders. The liver is unique in its natural regenerative capacity, but chronic damage can overwhelm this ability, leading to progressive fibrosis and eventually cirrhosis.
Liver fibrosis occurs when repeated injury triggers excessive deposition of collagen and scar tissue, replacing functional liver cells (hepatocytes). As fibrosis advances to cirrhosis, liver function deteriorates, leading to complications such as portal hypertension, ascites, hepatic encephalopathy, and liver failure.
While liver transplantation remains the definitive treatment for end-stage liver disease, donor organ shortages and surgical risks limit this option. Regenerative medicine offers a promising complementary approach, with MSC therapy showing potential to support liver repair, reduce fibrosis, and improve hepatic function.
Common Symptoms
- Fatigue and general weakness
- Abdominal pain or swelling
- Jaundice (yellowing of skin and eyes)
- Dark urine and pale stools
- Nausea and loss of appetite
- Easy bruising and bleeding
- Swelling in legs and ankles
How MSC Therapy May Help
MSCs demonstrate particularly strong potential for liver disease due to the liver's natural receptivity to regenerative signals. MSCs can migrate to damaged liver tissue and release hepatocyte growth factor (HGF), which supports the survival and proliferation of functional liver cells while inhibiting the activation of hepatic stellate cells responsible for fibrosis.
The anti-fibrotic properties of MSCs are central to their value in liver disease. They help downregulate the production of pro-fibrotic factors like TGF-beta and collagen, while upregulating matrix metalloproteinases (MMPs) that break down existing scar tissue. This may help shift the balance from fibrosis progression toward tissue remodeling and repair.
Additionally, MSCs provide powerful anti-inflammatory support that may help reduce hepatic inflammation, a key driver of ongoing liver damage. By modulating Kupffer cell activity and reducing pro-inflammatory cytokines, MSCs may create a more favorable environment for liver cells to recover and function normally.
Our Treatment Approach
Hepatic Assessment
Comprehensive liver evaluation including liver function tests, fibrosis scoring (FibroScan or equivalent), imaging, and viral hepatitis screening to determine disease severity.
IV MSC Infusion
Systemic intravenous delivery of MSCs targeting hepatic inflammation, fibrosis reduction, and support for liver cell regeneration and survival.
Anti-Fibrotic Protocol
Exosome co-therapy and complementary treatments designed to amplify anti-fibrotic effects and support the liver's natural regenerative capacity.
Hepatic Support
Nutritional guidance for liver health, avoidance of hepatotoxic substances, and ongoing monitoring of liver function markers to track improvements.
Expected Benefits
- May support liver cell regeneration and survival
- May help reduce hepatic fibrosis and scarring
- Supports reduction of liver inflammation
- May improve liver function markers
- Promotes healthy liver tissue remodeling
- May complement existing liver disease management
Frequently Asked Questions About Liver Disease
MSC therapy may help patients with compensated cirrhosis (early-stage) by reducing fibrosis, supporting liver cell regeneration, and improving liver function markers. For advanced decompensated cirrhosis, MSC therapy may provide supportive benefits but cannot replace a liver transplant if one is medically indicated.
Yes, MSC therapy shows promise for non-alcoholic fatty liver disease and steatohepatitis (NASH). The anti-inflammatory and anti-fibrotic properties of MSCs may help reduce liver inflammation and fibrosis associated with fatty liver conditions, supporting improved hepatic function.
MSCs release factors that inhibit hepatic stellate cells (the primary drivers of liver fibrosis) while producing enzymes (matrix metalloproteinases) that break down existing scar tissue. This dual action may help slow fibrosis progression and promote tissue remodeling.
We monitor liver function tests (ALT, AST, bilirubin, albumin), fibrosis scores, and imaging studies at regular intervals after treatment. Improvements, when observed, typically develop over 3-6 months and may include normalized liver enzymes and improved fibrosis staging.
Ready to Explore Your Treatment Options?
Schedule a personalized consultation to discuss how MSC therapy may support your health journey.